Riskpilot← Back to searchSign inGet full accessMULTIMERICS ApS
APSActiveCVR 31603390O B Muusvej 17Manufacture of pharmaceutical preparations · NACE 2120Est. 2008— employees
Revenue 2024
DKK -3K
-121% vs 2023
EBITDA margin
100.0%
-121% vs 2023
Equity ratio
62.8%
Financial strength
Net profit 2024
DKK -3K
-121% vs 2023
| Revenue | DKK -3K | -121% |
| EBITDA | DKK -3K | -121% |
| Net profit | DKK -3K | -121% |
| Total assets | DKK 16K | -5% |
| Equity | DKK 10K | -25% |
| Employees | — | — |
Legal name
MULTIMERICS ApS
CVR number
31603390
Legal form
Anpartsselskab
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
7. juli 2008
Share capital
DKK 125.000
Employees
—
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af bestyrelsens formand i forening med en direktør eller af den samlede bestyrelse.
Company purpose
Selskabets formål er Selskabets formål er at udvikle og kommercialisere funktionelle protein produkter til profylaktisk og terapeutisk brug ved passiv immunisering af dyr og mennesker samt al virksomhed, som efter bestyrelsens skøn er beslægtet hermed.
Address
O B Muusvej 17
Phone
+4520378751
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | -25 | -107 | -55 | -45 | 44 | -10 | -210 | -38 | -47 | -36 | -11 | 15 | -3 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBITDA | -25 | -107 | -55 | -45 | 44 | -10 | -210 | -38 | -47 | -36 | -11 | 15 | -3 |
| Depreciation & amort. | -0 | 1.655 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | -25 | -1.762 | -55 | -45 | 44 | -10 | -210 | -38 | -47 | -36 | -11 | 15 | -3 |
| Net financials | -171 | 0 | -0 | 1 | -0 | 0 | -0 | -0 | -0 | -1 | -1 | 0 | 0 |
| Profit before tax | -195 | -1.762 | -56 | -44 | 44 | -10 | -210 | -38 | -47 | -36 | -12 | 15 | -3 |
| Tax | -36 | -97 | -0 | -0 | -0 | -0 | -0 | -57 | -10 | -8 | -0 | -0 | -0 |
| Net profit | -160 | -1.665 | -56 | -44 | 44 | -10 | -210 | 19 | -37 | -28 | -12 | 15 | -3 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 1.778 | 414 | 29 | 5 | 135 | 152 | 38 | 56 | 69 | 85 | 69 | 16 | 16 |
| Equity | -534 | -2.199 | -2.255 | -2.299 | -2.255 | -2.265 | -2.475 | -2.456 | 37 | 9 | -2 | 13 | 10 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 2.312 | 2.613 | 2.284 | 2.304 | 2.391 | 2.418 | 2.513 | 2.512 | 32 | 76 | 72 | 3 | 6 |
| Total debt | 2.312 | 2.613 | 2.284 | 2.304 | 2.391 | 2.418 | 2.513 | 2.512 | 32 | 76 | 72 | 3 | 6 |
EBITDA margin
-330000.0%
This company
15.8%
Market median
-2088708% vs market
20122024
Equity ratio
62.8%
This company
38.2%
Market median
+64% vs market
20122024
Return on equity
-33.7%
This company
18.4%
Market median
-283% vs market
20122024
Net profit margin
-329200.0%
This company
8.1%
Market median
-4064298% vs market
20122024
Asset turnover
-0.21×
This company
1.12×
Market median
-119% vs market
20122024
Debt / equity
0.59×
This company
0.62×
Market median
+5% vs market
20122024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via CVR / Virk · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via CVR / Virk · Period 2012-01-01 – 2012-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
KB Management | Management | 2008 | — | — |
AO Chief Executive Officer | Chief Executive Officer | 2016 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2013 | — | — | |
| Chairman | 2008 | — | — | |
| Board of Directors | 2008 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
LPS Biosolutions A/S | Company | 100.0% | 100.0% | 2013 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
CHR. OLESEN HOLDING A/S
MULTIMERICS ApS Board members of MULTIMERICS ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Kirsten Bisgaard-Frantzen | Management | 0 companies |
| Allan Otto Fog Lihme | Chief Executive Officer | 0 companies |
| Bodil Ingrid Lindved | Board of Directors | 0 companies |
| Niels Jesper Jespersen Jensen | Chairman | 0 companies |
| Steen Palle Petersen | Board of Directors | 0 companies |